Rationale and design of the Chinese Atrial Fibrillation Registry Study

Du, Xin; Ma, Changsheng; Wu, Jiahui; Li, Songnan; Ning, Man; Tang, Ri‐Bo; Guo, Xueyuan; Long, Deyong; Yu, Rong‐Hui; Sang, Caihua; Jiang, Chen‐Xi; Zhang, Ting; Pan, Jianhong; Liu, Xiaohui; Lip, Gregory Y.H.

doi:10.1186/s12872-016-0308-1

Cited by 57 publications

(57 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The design and rationale of China‐AF study has been described previously 11 . In brief, China‐AF study is an ongoing prospective, multicenter, hospital‐based registry study enrolling AF patients from 31 tertiary and nontertiary hospitals in Beijing, China, with 18 hospitals providing AF ablation.…”

Section: Methodsmentioning

confidence: 99%

Effectiveness and safety of atrial fibrillation ablation in females

Sang

et al. 2020

Pacing Clinical Electrophis

Self Cite

View full text Add to dashboard Cite

Background Existing data on the effectiveness and safety of atrial fibrillation (AF) ablation in females are limited to studies of small sample size, lacking longer term follow‐up or adjustment for potential confounders. Methods A total of 6421 patients (2072 females) undergoing a first AF ablation procedure after enrollment in the Chinese Atrial Fibrillation Registry (China‐AF) study between August 2011 and December 2017 were analyzed. We evaluated the effectiveness (recurrence of documented [symptomatic or not] atrial tachyarrhythmia (AT)) and the safety (incidence of procedure‐related complications) of AF ablation in female patients compared to male patients. Sensitivity analyses based on routine data were also utilized to avoid potential sex differences in reporting of AF symptoms. Results Females were about 5 years older than males at the time of ablation (mean age 63.4 ± 9.5 vs 58.3 ± 10.8, P < .0001). A higher proportion of female patients had paroxysmal AF (74.3% vs 56.7%, P < .0001), hypertension (69.7% vs 61.3%, P < .0001), and hyperlipidemia (57.2% vs 52.9%, P = .001). Female sex was found to be an independent risk factor of AT recurrence in multivariate analyses (HR = 1.26, 95% CI 1.15‐1.38, P < .0001). These findings were confirmed in sensitivity analyses using only Holter data. Female sex was also associated with a higher risk of periprocedural complications after adjustment for baseline variables (OR = 1.41, 95% CI 1.03‐1.94, P = .03). Conclusions Female sex is an independent risk factor of AT recurrence and periprocedural complications after AF ablation.

show abstract

Section: Methodsmentioning

confidence: 99%

Effectiveness and safety of atrial fibrillation ablation in females

Sang

et al. 2020

Pacing Clinical Electrophis

Self Cite

View full text Add to dashboard Cite

show abstract

“…The China‐AF study is a prospective, multicenter, hospital‐based registry study of participants diagnosed with AF. Details of the study design have been published previously . Participants were enrolled from inpatients and outpatients in 19 tertiary and 12 nontertiary hospitals located in central and subrural areas of Beijing.…”

Section: Methodsmentioning

confidence: 99%

“…Details of the study design have been published previously. 12 Participants were enrolled from inpatients and outpatients in 19 tertiary and 12 nontertiary hospitals located in central and subrural areas of Beijing. Eligible participants needed to be 18 years or older, had 12 leads electrocardiogram (ECG), pacemaker/implantable cardioverter defibrillator ECG, or Holter ECG (>30 seconds) which documented AF within the past 6 months, and agreed to be followed up.…”

Section: Methodsmentioning

confidence: 99%

Prevalence of modifiable risk factors and relation to stroke and death in patients with atrial fibrillation: A report from the China atrial fibrillation registry study

Jiang

Lan

et al. 2019

Cardiovasc electrophysiol

Self Cite

View full text Add to dashboard Cite

Background Lifestyle and risk factor management may improve outcomes in patients with atrial fibrillation (AF). We aim to evaluate the prevalence of modifiable risk factors and how these factors impact clinical outcomes in patients with AF. Methods and Results Data on 17 898 AF cohort patients with AF enrolled between 2011 and 2016 was analyzed. A healthy lifestyle was defined as not smoking, not drinking, a healthy body mass index (BMI), untreated total cholesterol less than 200 mg/dL, untreated blood pressure (BP) less than 120/80 mm Hg, and untreated fasting plasma glucose (FPG) less than 100 mg/dL. The association between risk factors and risk of the composite endpoint of all‐cause mortality and nonfatal ischemic stroke were assessed using Cox proportional hazards regression model. Only 4.0% of patients achieved a healthy lifestyle. In multivariate analysis, current smoking, a low BMI, not well‐controlled FPG were independently and significantly associated with higher risk of all‐cause mortality and nonfatal ischemic stroke, with corresponding hazard ratio (HR) estimates 1.22 (95% confidence interval [CI], 1.00‐1.47), HR = 1.72 (95% CI, 1.34‐2.20), and HR = 1.25 (95% CI, 1.06‐1.46), respectively. High BP was also associated with higher risk with the outcomes (HR = 1.15, 95% CI, 1.00‐1.34). Compared with patients with no risk factor, those who failed to maintained or achieved optimal risk factor control had a progressively higher risk of death and nonfatal ischemic stroke (HR for 1 risk factor = 1.44; 95% CI, 1.07‐1.92; and more than 2 risk factors = 1.75; 95% CI, 0.99‐3.09). Conclusions Maintenance of well‐controlled risk factors may substantially lower the risk of death and ischemic stroke in patients with AF.

show abstract

“…Numerous registries and surveys have been described in different European, Asian, and American countries [ 7 - 13 , 16 - 19 ], but few contemporary data on the demographic characteristics, outcome of AF patients, and quality of anticoagulation control achieved in AF patients receiving routine medical care are available in North Africa and especially in Tunisia.…”

Section: Discussionmentioning

confidence: 99%

“…Numerous registries and surveys have been described in different European, Asian, and American countries—Euro Observational Research Programme–Atrial Fibrillation pilot general registry [ 7 ], Japanese Rhythm Registry [ 8 ], Global Anticoagulant Registry in the Field [ 9 ], Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation [ 10 ], the nationwide US Practice Innovation and Clinical Excellence Registry [ 11 ], Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ 12 ], and Chinese Atrial Fibrillation Registry study [ 13 ]. However, few data on the demographic characteristics, outcome of AF patients, and quality of anticoagulation control achieved in AF patients receiving routine medical care are available in North Africa and especially in Tunisia.…”

Section: Introductionmentioning

confidence: 99%

Design and Rationale of the National Tunisian Registry of Atrial Fibrillation: Protocol for a Prospective, Multicenter Trial

Halima¹,

Ouali²,

Mourali³

et al. 2018

JMIR Res Protoc

View full text Add to dashboard Cite

BackgroundAtrial fibrillation (AF) is an important health problem in Tunisia. A significant change in the epidemiological pattern of heart disease has been seen in the last 3 decades; however, no large prospective multicenter trial reflecting national data has been published so far. Robust data on the contemporary epidemiological profile and management of AF patients in Tunisia are limited.ObjectiveThe aim of this study is to analyze, follow, and evaluate patients with AF in a large multicenter nationwide trial.MethodsA total of 1800 consecutive patients with AF by electrocardiogram, reflecting all populations of all geographical regions of Tunisia, will be included in the study, with the objective of describing the epidemiological pattern of AF. Patients will be officially enrolled in the National Tunisian Registry of Atrial Fibrillation (NATURE-AF) only if an electrocardiogram diagnosis (12-lead, 24-hour Holter, or other electrocardiographic documentation) confirming AF is made. The qualifying episode of AF should have occurred within the last year, and patients do not need to be in AF at the time of enrollment. Patients will be followed for 1 year. Incidence of stroke or transient ischemic attack, thromboembolic events, and cardiovascular death will be recorded as the primary end point, and hemorrhagic accidents, measurement of international normalized ratio, and time in therapeutic range will be recorded as secondary end points.ResultsResults will be available at the end of the study; the demographic profile and general risk profile of Tunisian AF patients, frequency of anticoagulation, frequency of effective treatment, and risks of thromboembolism and bleeding will be evaluated according to the current guidelines. Major adverse events will be determined. NATURE-AF will be the largest registry for North African AF patients.ConclusionsThis study would add data and provide a valuable opportunity for real-world clinical epidemiology in North African AF patients with insights into the uptake of contemporary AF management in this developing region.Trial RegistrationClinicalTrials.gov NCT03085576; https://clinicaltrials.gov/ct2/show/NCT03085576 (Archived by WebCite at http://www.webcitation.org/6zN2DN2QX)Registered Report IdentifierRR1-10.2196/8523

show abstract

Rationale and design of the Chinese Atrial Fibrillation Registry Study

Cited by 57 publications

References 22 publications

Effectiveness and safety of atrial fibrillation ablation in females

Effectiveness and safety of atrial fibrillation ablation in females

Prevalence of modifiable risk factors and relation to stroke and death in patients with atrial fibrillation: A report from the China atrial fibrillation registry study

Design and Rationale of the National Tunisian Registry of Atrial Fibrillation: Protocol for a Prospective, Multicenter Trial

Contact Info

Product

Resources

About